Good News From the FDA Should Fuel Abiomed’s Growth Into the Future

Good News From the FDA Should Fuel Abiomed’s Growth Into the Future

Source: 
Motley Fool
snippet: 

Abiomed (NASDAQ: ABMD) has enjoyed tremendous success over the last seven years. At the start of 2013, the company traded at $14 and today its stock price is $183. The medical device maker's main product is the Impella line of heart pumps, devices that are inserted percutaneously (through the skin) which improve blood flow and act as a heart pump.